Monoamine Receptors in Postmortem Brain: Do Postmortem Brain Studies Cloud or Clarify our Understanding of the Affective Disorders?

  • Craig A. Stockmeier
  • George Jurjus
Part of the Neurobiological Foundation of Aberrant Behaviors book series (NFAB, volume 4)

Abstract

Despite considerable research efforts, it has been difficult to reach definitive conclusions in postmortem brain tissue on monoamine receptors and transporters in suicide and affective disorders. Most studies cannot be directly compared for a number of methodological reasons. Critical issues to control in future postmortem brain studies include variables such as the cause of death (e.g. suicide), the specific psychiatric diagnoses of the subjects, long-term medication histories, psychoactive substance use by the subjects, smoking history, the hemisphere from which tissues were dissected, and the specific cytoarchitectonic region to be evaluated. Carefully controlled studies with larger numbers of subjects will ensure a greater likelihood of reaching a consensus on the influence of suicide and psychiatric history on monoaminergic markers in postmortem brain tissue.

Keywords

Prefrontal Cortex Locus Coeruleus Serotonin Transporter Postmortem Brain Dorsal Raphe Nucleus 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Aghajanian GK, Sprouse JS, Rasmussen K.: Physiology of the midbrain 5HT system. In: Meltzer HY (editor). Psychophamtacology: The Third Generation of Progress. Raven Press, New York, 1987; pp. 141–148.Google Scholar
  2. Arango V, Ernsberger P, Marzuk PM, Chen JS, Tierney H, Stanley M, Reis DJ, Mann JJ.: Autoradiographic demonstration of increased serotonin 5-HT2 and beta-adrenergic receptor binding sites in the brain of suicide victims. Arch Gen Psychiatry 1990; 47: 1038–1047.PubMedGoogle Scholar
  3. Arango V, Underwood MD, Mann JJ.: Alterations in monoamine receptors in the brain of suicide victims. J Clin Psychopharmacol 1992; 12: 8S - 12S.PubMedGoogle Scholar
  4. Arango V, Emsberger P, Sved AF, Mann M.: Quantitative autoradiography of alpha 1- and alpha 2-adrenergic receptors in the cerebral cortex of controls and suicide victims. Brain Res 1993; 630: 271–282.PubMedGoogle Scholar
  5. Arango V, Underwood MD, Gubbi AV, Mann JJ.: Localized alterations in pre-and postsynaptic serotonin binding sites in the ventrolateral prefrontal cortex of suicide victims. Brain Res 1995; 688: 121–133.PubMedGoogle Scholar
  6. Arango V, Underwood MD, Mann JJ.: Fewer pigmented locus coeruleus neurons in suicide victims: preliminary results. Biol Psychiatry 1996; 39: 112–120.PubMedGoogle Scholar
  7. Arora RC, Meltzer HY.: H-imipramine binding in the frontal cortex of suicides. Psychiatry Res 1989; 30: 125–135.PubMedGoogle Scholar
  8. Arora RC, Meltzer HY.: Serotonergic measures in the brains of suicide victims. 5-HT2 binding sites in the frontal cortex of suicide victims and control subjects. Am J Psychiatry 1989; 146: 730–736.PubMedGoogle Scholar
  9. Arranz B, Marcusson J.: [3H]paroxetine and [3H]citalopram as markers of the human brain 5-HT uptake site: a comparison study. J Neural Transm Gen Sect 1994; 97: 27–40.PubMedGoogle Scholar
  10. Arranz B, Eriksson A, Mellerup E, Plenge P, Marcusson J.: Brain 5-HT1A, 5-HTID, and 5-HT2 receptors in suicide victims. Biol Psychiatry 1994; 35: 457–463.PubMedGoogle Scholar
  11. Attar-Levy D, Martinot JL, Blin J, Dao-Castellana MH, Crouzel C, Mazoyer B, Poirier MF, Bourdel MC, Aymard N, Syrota A, Feline A.: The cortical serotonin2 receptors studied with positron-emission tomography and [18F]-setoperone during depressive illness and antidepressant treatment with clomipramine. Biol Psychiatry 1999; 45: 180–186.PubMedGoogle Scholar
  12. Barraclough B, Bunch J, Nelson B, Sainsbury P.: A hundred cases of suicide: clinical aspects. Br J Psychiatry 1974; 125: 355–373.PubMedGoogle Scholar
  13. Biegon A, Israeli M.: Regionally selective increases in beta-adrenergic receptor density in the brains of suicide victims. Brain Res 1988; 442: 199–203.PubMedGoogle Scholar
  14. Biver F, Wikler D, Lotstra F, Damhaut P, Goldman S, Mendlewicz J.: Serotonin 5-HT2 receptor imaging in major depression: focal changes in orbito-insular cortex. Br J Psychiatry 1997; 171: 444–448.PubMedGoogle Scholar
  15. Blier P, de Montigny C.: Current advances and trends in the treatment of depression. Trends in Pharmacological Science 1994; 15: 220–226.Google Scholar
  16. Bligh-Glover W, Kolli T, Balraj E, Friedman L, Shapiro L, Dilley G, Stockmeier C.: Subregional distribution of serotonin transporters in the midbrain of suicide victims with major depression. Biol Psychiatry 2000; 47: 1015–1024.PubMedGoogle Scholar
  17. Bondy B, Kuznik J, Baghai T, Schule C, Zwanzger P, Minov C, de Jonge S, Rupprecht R, Meyer H, Engel RR, Eisenmenger W, Ackenheil M.: Lack of association of serotonin2A receptor gene polymorphism (T102C) with suicidal ideation and suicide. Am J Med Genet 2000; 96: 831–835.PubMedGoogle Scholar
  18. Bowden C, Cheetham SC, Lowther S, Katona CL, Crompton MR, Horton RW.: Dopamine uptake sites, labelled with [3H]GBR12935, in brain samples from depressed suicides and controls. Eur Neuropsychopharmacol 1997; 7: 247–252.PubMedGoogle Scholar
  19. Bowden C, Theodorou AE, Cheetham SC, Lowther S, Katona CL, Crompton MR, Horton RW.: Dopamine D1 and D2 receptor binding sites in brain samples from depressed suicides and controls. Brain Res 1997; 752: 227–233.PubMedGoogle Scholar
  20. Burnet PW, Eastwood SL, Harrison PJ.: [3H]WAY-100635 for 5-HT1A receptor autoradiography in human brain: a comparison with [3H]8-OH-DPAT and demonstration of increased binding in the frontal cortex in schizophrenia. Neurochem Int 1997; 30: 565–574.PubMedGoogle Scholar
  21. Callado LF, Meana JJ, Grijalba B, Pazos A, Sastre M, Garcia-Sevilla JA.: Selective increase of alpha2A-adrenoceptor agonist binding sites in brains of depressed suicide victims. J Neurochem 1998; 70: 1114–1123.PubMedGoogle Scholar
  22. Cheetham SC, Crompton MR, Katona CL, Horton RW.: Brain 5-HT2 receptor binding sites in depressed suicide victims. Brain Res 1988; 443: 272–280.PubMedGoogle Scholar
  23. Cheetham SC, Crompton MR, Katona CL, Horton RW.: Brain 5-HT1 binding sites in depressed suicides. Psychopharmacology (Berl) 1990; 102: 544–548.Google Scholar
  24. Cheng AT.: Mental illness and suicide. A case-control study in east Taiwan. Arch Gen Psychiatry 1995; 52: 594–603.PubMedGoogle Scholar
  25. Crow TJ, Cross AJ, Cooper SJ, Deakin JFW, Ferrier IM, Johnson JA, Joseph MH, Owen F, Poulter M, Lofthouse R, Corsellis JAN, Chambers DR, Blessed G, Perry EK, Perry RH, Tomlinson BE.: Neurotransmitter receptors and monoamine metabolites in brain of patients with Alzheimer-type dementia and depression, and suicides. Neuropharmacology 1984; 23: 1561–1569.PubMedGoogle Scholar
  26. De Paermentier F, Manger JM, Lowther S, Crompton MR, Katona CL, Horton RW.: Brain alpha-adrenoceptors in depressed suicides. Brain Res 1997; 757: 60–68.PubMedGoogle Scholar
  27. De Paermentier F, Cheetham SC, Crompton MR, Katona CL, Horton RW.: Brain betaadrenoceptor binding sites in antidepressant-free depressed suicide victims. Brain Res 1990; 525: 71–77.PubMedGoogle Scholar
  28. D’haenen H, Bossuyt A, Mertens J, Bossuyt-Piron C, Gijsemans M, Kaufman L.: SPECT imaging of serotonin2 receptors in depression. Psychiatry Res 1992; 45: 227–237.PubMedGoogle Scholar
  29. Dillon KA, Gross-Isseroff R, Israeli M, Biegon A.: Autoradiographic analysis of serotonin 5HT1A receptor binding in the human brain postmortem: effects of age and alcohol. Brain Res 1991; 554: 56–64.PubMedGoogle Scholar
  30. Drevets WC, Frank E, Price JC, Kupfer DJ, Holt D, Greer PJ, Huang Y, Gautier C, Mathis C.: PET imaging of serotonin IA receptor binding in depression. Biol Psychiatry 1999; 46: 1375–1387.PubMedGoogle Scholar
  31. Fu CH, Reed LI, Meyer JH, Kennedy S, Houle S, Eisfeld BS, Brown GM.: Noradrenergic dysfunction in the prefrontal cortex in depression. Biol Psychiatry 2001; 49: 317–325.PubMedGoogle Scholar
  32. Garcia-Sevilla JA, Escriba PV, Sastre M, Walzer C, Busquets X, Jaquet G, Reis DJ, Guimon J.: Immunodetection and quantitation of imidazoline receptor proteins in platelets of patients with major depression and in brains of suicide victims. Arch Gen Psychiatry 1996; 53: 803–810.PubMedGoogle Scholar
  33. Garcia-Sevilla JA, Escriba PV, Ozaita A, La Harpe R, Walzer C, Eytan A, Guimon J.: Up-regulation of immunolabeled alpha2A-adrenoceptors, Gi coupling proteins, and regulatory receptor kinases in the prefrontal cortex of depressed suicides. J Neurochem 1999; 72: 282–291.PubMedGoogle Scholar
  34. Gonzalez AM, Pascual J, Meana JJ, Barturen F, del Arco C, Pazos A, Garcia-Sevilla JA.: Autoradiographic demonstration of increased alpha 2-adrenoceptor agonist binding sites in the hippocampus and frontal cortex of depressed suicide victims. J Neurochem 1994; 63: 256–265.PubMedGoogle Scholar
  35. Gozlan H, Thibault S, Laporte AM, Lima L, Hamon M.: The selective 5-HT1A antagonist radioligand [3H]WAY 100635 labels both G-protein-coupled and free 5-HTIA receptors in rat brain membranes. Eur J Pharmacol 1995; 288: 173–186.PubMedGoogle Scholar
  36. Gross-Isseroff R, Israeli M, Biegon A.: Autoradiographic analysis of tritiated imipramine binding in the human brain postmortem: effects of suicide. Arch Gen Psychiatry 1989; 46: 237–241.PubMedGoogle Scholar
  37. Gross-Isseroff R, Dillon KA, Fieldust SJ, Biegon A.: Autoradiographic analysis of alpha 1noradrenergic receptors in the human brain postmortem. Effect of suicide. Arch Gen Psychiatry 1990; 47: 1049–1053.PubMedGoogle Scholar
  38. Gross-Isseroff R, Salama D, Israeli M, Biegon A.: Autoradiographic analysis of [3H]ketanserin binding in the human brain postmortem: effect of suicide. Brain Res 1990; 507: 208–215.PubMedGoogle Scholar
  39. Gurevich EV, Joyce JN.: Comparison of [3H]paroxetine and [3H]cyanoimipramine for quantitative measurement of serotonin transporter sites in human brain. Neuropsychopharmacology 1996; 14: 309–323.PubMedGoogle Scholar
  40. Hoyer D, Vos P, Closse A, Pazos A, Palacios JM, Davies H.: [3H]ketanserin labels 5-HT2 receptors and alpha 1-adrenoceptors in human and pig brain membranes. Naunyn Schmiedebergs Arch Pharmacol 1987; 335: 226–230.PubMedGoogle Scholar
  41. Hrdina PD, Demeter E, Vu TB, Sùtùnyi P, Palkovits M.: 5-HT uptake sites and 5-HT receptors in brain of antidepressant-free suicide victims/depressives: increase in 5-HT2 sites in cortex and amygdala. Brain Res 1993; 614: 37–44.PubMedGoogle Scholar
  42. Huang YY, Grailhe R, Arango V, Hen R, Mann JJ.: Relationship of psychopathology to the human serotoninl B genotype and receptor binding kinetics in postmortem brain tissue. Neuropsychopharmacology 1999; 21: 238–246.PubMedGoogle Scholar
  43. Hurd YL, Herman MM, Hyde TM, Bigelow LB, Weinberger DR, Kleinman JE.: Prodynorphin mRNA expression is increased in the patch vs matrix compartment of the caudate nucleus in suicide subjects. Mol Psychiatry 1997; 2: 495–500.PubMedGoogle Scholar
  44. Joyce JN, Shane A, Lexow N, Winokur A, Casanova MF, Kleinman JE.: Serotonin uptake sites and serotonin receptors are altered in the limbic system of schizophrenics. Neuropsychopharmacology 1993; 8: 315–336.PubMedGoogle Scholar
  45. Kelly TM, Mann JJ.: Validity of DSM-III-R diagnosis by psychological autopsy: a comparison with clinician ante-mortem diagnosis. Acta Psychiatr Scand 1996; 94: 337–343.PubMedGoogle Scholar
  46. Kent JM.: SNaRls, NaSSAs, and NaRIs: new agents for the treatment of depression. Lancet 2000; 355 (9207): 911–918.PubMedGoogle Scholar
  47. Klimek V, Stockmeier C, Overholser J, Meltzer HY, Kalka S, Dilley G, Ordway GA.: Reduced levels of norepinephrine transporters in the locus coeruleus in major depression. J Neuroscience 1997; 17: 8451–8458.Google Scholar
  48. Klimek V, Rajkowska G, Luker SN, Dilley GE, Meltzer HY, Overholser JC, Stockmeier CA, Ordway GA.: Brain noradrenergic receptors in major depression and schizophrenia. Neuropsychopharmacology 1999; 21: 69–81.PubMedGoogle Scholar
  49. Klimek V, Zhu M-Y, Dilley G, Overholser JC, Meltzer HY, Stockmeier CA, Ordway GA.: Neurochemical evidence for a link between cigarette smoking and depression. Soc. Neuroscience Abstract 1999; 25: 2139.Google Scholar
  50. Klimek V, Schenck JE, Dilley G, Overholser JC, Meltzer HY, Stockmeier CA, Ordway GA.: Low dopamine transporter in the amygdala in major depression. Soc. Neuroscience Abstract 2000; 26: 1764.Google Scholar
  51. Lamelle M, Abi-Dargham A, Casanova MF, Toti R, Weinberger DR, Kleinman JE.: Selective abnormalities of prefrontal serotonergic receptors in schizophrenia. Arch Gen Psychiatry 1993; 50: 810–818.Google Scholar
  52. Laruelle M, Abi-Dargham A, Casanova MF, Toti R, Weinberger DR, Kleinman JE.: Selective abnormalities of prefrontal serotonergic receptors in schizophrenia. A postmortem study. Arch Gen Psychiatry 1993; 50: 810–818.PubMedGoogle Scholar
  53. Lawrence KM, De Paermentier F, Cheetham SC, Crompton MR, Katona CL, Horton RW.: Brain 5-HT uptake sites, labelled with [3H]paroxetine, in antidepressant-free depressed suicides. Brain Res 1990; 526: 17–22.PubMedGoogle Scholar
  54. Lawrence KM, Kanagasundaram M, Lowther S, Katona CL, Crompton MR, Horton RW.: [3H] imipramine binding in brain samples from depressed suicides and controls: 5-HT uptake sites compared with sites defined by desmethylimipramine. J Affect Disord 1998; 47: 105–112.PubMedGoogle Scholar
  55. Leake A, Fairbairn AF, McKeith IG, Ferrier IN.: Studies on the serotonin uptake binding site in major depressive disorder and control postmortem brain: neurochemical and clinical correlates. Psychiatry Res 1991; 39: 155–165.PubMedGoogle Scholar
  56. Little KY, Clark TB, Ranc J, Duncan GE.: Beta-adrenergic receptor binding in frontal cortex from suicide victims. Biol Psychiatry 1993; 39: 596–605.Google Scholar
  57. Little KY, McLauglin DP, Ranc J, Gilmore J, Lopez JF, Watson SJ, Carroll FI, Butts JD.: Serotonin transporter binding sites and mRNA levels in depressed persons committing suicide. Biol Psychiatry 1997; 41: 1156–1164.PubMedGoogle Scholar
  58. Lowther S, De Paermentier F, Cheetham SC, Crompton MR, Katona CL, Horton RW.: 5HTIA receptor binding sites in postmortem brain samples from depressed suicides and controls. J Affect Disord 1997; 42: 199–207.PubMedGoogle Scholar
  59. Lowther S, De Paermentier F, Crompton MR, Katona CL, Horton RW.: Brain 5-HT2 receptors in suicide victims: violence of death, depression and effects of antidepressant treatment. Brain Res 1994; 642: 281–289.PubMedGoogle Scholar
  60. Lowther S, Katona CL, Crompton MR, Horton RW.: 5-HTID and 5-HTIE/1F binding sites in depressed suicides: increased 5-HT1D binding in globus pallidus but not cortex. Mol Psychiatry 1997; 2: 314–321.PubMedGoogle Scholar
  61. Malison RT, Price LH, Berman R, van Dyke CH, Pelton G, Carpenter L, Sanacora G, Owens MJ, Nemeroff CB, Rajeevan N, Baldwin RM, Seibyl JP, Innis RB, Charney DS.: Reduced brain serotonin transporter availability in major depression as measured by [’23I]-20-carbomethoxy-313-(4-iodophenyl)tropane and Single Photon Emission Computed Tomography. Biol Psychiatry 1998; 44: 1090–1098.PubMedGoogle Scholar
  62. Mann JJ, Stanley M, McBride PA, McEwen BS.: Increased serotonin2 and beta-adrenergic receptor binding in the frontal cortices of suicide victims. Arch Gen Psychiatry 1986; 43: 954–959.PubMedGoogle Scholar
  63. Mann JJ, Henteleff RA, Lagattuta TF, Perper JA, Li S, Arango V.: Lower 3H-paroxetine binding in cerebral cortex of suicide victims is partly due to fewer high affinity, non-transporter sites. J Neural Transm 1996; 103: 1337–1350.PubMedGoogle Scholar
  64. Mann JJ, Arango V, Henteleff RA, Lagattuta TF, Wong DT.: Serotonin 5-HT3 receptor binding kinetics in the cortex of suicide victims are normal. J Neural Transm 1996; 03: 165–171.Google Scholar
  65. Mann JJ, Huang YY, Underwood MD, Kassir SA, Oppenheim S, Kelly TM, Dwork AJ, Arango V.: A serotonin transporter gene promoter polymorphism (5-HTTLPR) and prefrontal cortical binding in major depression and suicide. Arch Gen Psychiatry 2000; 57: 729–738.PubMedGoogle Scholar
  66. Martinot M, Bragulat V, Artiges E, Dolle F, Hinnen F, Jouvent R, Martinot J.: Decreased presynaptic dopamine function in the left caudate of depressed patients with affective flattening and psychomotor retardation. Am J Psychiatry 2001; 158: 314–316.PubMedGoogle Scholar
  67. Matsubara S, Arora RC, Meltzer HY.: Serotonergic measures in suicide brain: 5-HT-1A binding sites in frontal cortex of suicide victims. J Neural Transm 1991; 85: 181–194Google Scholar
  68. Maura G, Thellung S, Andrioli GC, Ruelle A, Raiteri M.: Release-regulating serotonin 5- HTID autoreceptors in human cerebral cortex. J Neurochem 1993; 60: 1179–1182.PubMedGoogle Scholar
  69. McKeith IG, Marshall EF, Ferrier IN, Armstrong MM, Kennedy WN, Perry RH, Perry EK, Eccleston D.: 5-HT receptor binding in postmortem brain from patients with affective disorder. J Affect Disord 1987; 13: 67–74.PubMedGoogle Scholar
  70. Meana JJ, Barturen F, Garcia-Sevilla JA.: Alpha 2-adrenoceptors in the brain of suicide victims: increased receptor density associated with major depression. Biol Psychiatry 1992; 31: 471–490.PubMedGoogle Scholar
  71. Meana JJ, Garcia-Sevilla JA.: Increased alpha 2-adrenoceptor density in the frontal cortex of depressed suicide victims. J Neural Transm. 1987; 70: 377–381.PubMedGoogle Scholar
  72. Meyer JH, Kapur S, Eisfeld B, Brown GM, Houle S, DaSilva J, Wilson AA, Rafi-Tari S, Mayberg HS, Kennedy SH.: The effect of paroxetine on 5-HT(2A) receptors in depression: An [I8F]setoperone PET imaging study. Am J Psychiatry 2001; 158: 78–85.PubMedGoogle Scholar
  73. Meyer JH, Kapur S, Houle S, DaSilva J, Owczarek B, Brown GM, Wilson AA, Kennedy SH.: Prefrontal cortex 5-HT2 receptors in depression: an [18F]setoperone PET imaging study. Am J Psychiatry 1999; 156: 1029–1034.PubMedGoogle Scholar
  74. Meyerson LR, Wennogle LP, Abel MS, Coupet J, Lippa AS, Rauh CE, Beer B.: Human brain receptor alterations in suicide victims. Pharmacol Biochem Behav 1982; 17: 159–163.PubMedGoogle Scholar
  75. Bloom FE, Morales M.: The central 5-HT3 receptor in CNS disorders. Neurochem Res 1998; 23: 653–659.PubMedGoogle Scholar
  76. Ongur D, Drevets WC, Price JL.: Glial reduction in the subgenual prefrontal cortex in mood disorders. Proc Natl Acad Sci U S A 1998; 95: 13290–13295.PubMedGoogle Scholar
  77. Oquendo MA, Mann JJ.: The biology of impulsivity and suicidality. Psychiatr Clin North Am 2000; 2311–2325.Google Scholar
  78. Ordway GA, Streator-Smith K, Haycock JW.: Elevated tyrosine hydroxylase in the locus coeruleus of suicide victims. J Neurochem 1994; 62: 680–685.PubMedGoogle Scholar
  79. Ordway GA, Widdowson PS, Smith KS, Halaris A.: Agonist binding to alpha 2-adrenoceptors is elevated in the locus coeruleus from victims of suicide. J Neurochem 1994; 63: 617–624.PubMedGoogle Scholar
  80. Ordway GA, Farley JT, Dilley GE, Overholser JC, Meltzer HY, Balraj EK, Stockmeier CA, Klimek V.: Quantitative distribution of monoamine oxidase A in brainstem monoamine nuclei is normal in major depression. Brain Res 1999; 847: 71–79.PubMedGoogle Scholar
  81. Ordway GA, Schenck JE, Dilley GE, Overholser JC, Meltzer HY, Stockmeier CA, Halaris AE, Klimek V.: Increased p-[125I]iodoclonidine binding to alpha-2 adrenoceptors in the locus coeruleus in major depression. Soc Neuroscience Abstract 1999; 25: 2139.Google Scholar
  82. Owen F, Chambers DR, Cooper SJ, Crow TJ, Johnson JA, Lofthouse R, Poulter M.: Serotonergic mechanisms in brains of suicide victims. Brain Res 1986; 362: 185–188.PubMedGoogle Scholar
  83. Owen F, Cross A.I, Crow TJ, Deakin JFW, Ferrier IM, Lofthouse R, Poulter M.: Brain 5HT-2 receptors and suicide. Lancet 1983; 2: 1256PubMedGoogle Scholar
  84. Palego L, Marazziti D, Rotondo A, Batistini A, Lucacchini A, Naccarato AG, Bevilacqua G, Borsini F, Ladinsky H, Cassano GB.: Further characterization of [3H]8-hydroxy-2-(di-npropyl)aminotetralin binding sites in human brain postmortem. Neurochem Int 1997; 30: 149–157.PubMedGoogle Scholar
  85. Parsey RV, Oquendo MA, Zea-Ponce Y, Rodenhiser-Hill J, Kegeles LS, Pratap M, Cooper TB, Van Heertum RL, Mann JJ, Laruelle M.: Dopamine D2 receptor availability and amphetamine-induced dopamine release in unipolar depression. Biol Psychiatry 2001; in press.Google Scholar
  86. Piletz JE, Ordway GA, Zhu H, Duncan BJ, Halaris A.: Autoradiographic Comparison of [3H]clonidine binding to non-adrenergic sites and alpha2-adrenergic receptors in human brain. Neuropsychopharmacology 2000b; 23: 697–708.PubMedGoogle Scholar
  87. Piletz JE, Zhu H, Ordway G, Stockmeier C, Dilly G, Reis D, Halaris A.: Imidazoline receptor proteins are decreased in the hippocampus of individuals with major depression. Biol Psychiatry 2000a; 48: 910–919.PubMedGoogle Scholar
  88. Pineyro G, Blier P, Dennis T, de Montigny C.: Desensitization of the neuronal 5-HT carrier following its long-term blockade. J Neurosci 1994; 14: 3036–3047.PubMedGoogle Scholar
  89. Rajkowska G, Goldman-Rakic PS.: Cytoarchitectonic definition of prefrontal areas in the normal human cortex: I. Remapping of areas 9 and 46 using quantitative criteria. Cereb Cortex 1995; 5: 307–322.PubMedGoogle Scholar
  90. Rajkowska G, Miguel-Hidalgo JJ, Wei J, Dilley G, Pittman SD, Meltzer HY, Overholser JC, Roth BL, Stockmeier CA.: Morphometric evidence for neuronal and glial prefrontal cell pathology in major depression. Biol Psychiatry 1999 45: 1085–1098.PubMedGoogle Scholar
  91. Rajkowska G.: Histopathology of the prefrontal cortex in major depression: what does it tell us about dysfunctional monoaminergic circuits? Prog Brain Res 2000; 126: 397–412.PubMedGoogle Scholar
  92. Rajkowska G, Halaris A, Selemon LD.: Reductions in neuronal and glial density characterize the dorsolateral prefrontal cortex in bipolar disorder. Biol Psychiatry 2001; in press.Google Scholar
  93. Ramboz S, Saudou F, Amara DA, Belzung C, Segu L, Misslin R, Buhot MC, Hen R.: 5-HT1B receptor knock out-behavioral consequences. Behav Brain Res 1996; 73: 305–312.PubMedGoogle Scholar
  94. Rich CL, Young D, Fowler RC.: San Diego suicide study. I. Young vs old subjects. Arch Gen Psychiatry 1986; 43: 577–582.PubMedGoogle Scholar
  95. Sargent PA, Kjaer KH, Bench CJ, Rabiner EA, Messa C, Meyer J, Gunn RN, Grasby PM, Cowen PJ.: Brain serotonin1A receptor binding measured by positron emission tomography with [11C]WAY-100635: effects of depression and antidepressant treatment. Arch Gen Psychiatry 2000; 57: 174–180.PubMedGoogle Scholar
  96. Sastre M, Garcia-Sevilla JA.: Densities of I2-imidazoline receptors, alpha 2-adrenoceptors and monoamine oxidase B in brains of suicide victims. Neurochem Int 1997; 30: 63–72.PubMedGoogle Scholar
  97. Staley JK, Malison RT, Innis RB.: Imaging of the serotonergic system: interactions of neuroanatomical and functional abnormalities of depression. Biol Psychiatry 1998; 44: 534–549.PubMedGoogle Scholar
  98. Stanley M, Mann JJ.: Increased serotonin-2 binding sites in frontal cortex of suicide victims. Lancet 1983; 29: 214–216.Google Scholar
  99. Stanley M, Mann JJ.: Suicide and serotonin receptors. Lancet 1984; 11; 1: 349.Google Scholar
  100. Stanley M, Virgilio J, Gershon S.: Tritiated imipramine binding sites are decreased in the frontal cortex of suicides. Science 1982; 216: 1337–1339.PubMedGoogle Scholar
  101. Stockmeier CA, Meltzer HY.: Beta-adrenergic receptor binding in frontal cortex of suicide victims. Biol Psychiatry 1991; 29: 183–191.PubMedGoogle Scholar
  102. Stockmeier CA, Dilley GE, Shapiro LA, Overholser JC, Thompson PA, Meltzer HY.: Serotonin receptors in suicide victims with major depression. Neuropsychopharmacology 1997; 16: 162–73.PubMedGoogle Scholar
  103. Stockmeier CA, Shapiro LA, Dilley GE, Kolli TN, Friedman L, Rajkowska G.: Increase in serotonin-1A autoreceptors in the midbrain of suicide victims with major depression-postmortem evidence for decreased serotonin activity. J Neurosci 1998; 18: 7394–7401.PubMedGoogle Scholar
  104. Sumiyoshi T, Stockmeier CA, Overholser JC, Thompson PA, Meltzer HY.: Dopamine D4 receptors and effects of guanine nucleotides on [3H]raclopride binding in postmortem caudate nucleus of subjects with schizophrenia or major depression. Brain Res 1995; 681: 109–116.PubMedGoogle Scholar
  105. Turecki G, Briere R, Dewar K, Antonetti T, Lesage AD, Seguin M, Chawky N, Vanier C, Alda M, Joober R, Benkelfat C, Rouleau GA.: Prediction of level of serotonin 2A receptor binding by serotonin receptor 2A genetic variation in postmortem brain samples from subjects who did or did not commit suicide. Am J Psychiatry 1999; 156: 1456–1458.PubMedGoogle Scholar
  106. Uylings HB, Sanz Arigita E, de Vos K, Smeets WJ, Pool CW, Amunts K, Rajkowska G, Zilles K.: The importance of a human 3D database and atlas for studies of prefrontal and thalamic functions. Prog Brain Res 2000; 126: 357–368.PubMedGoogle Scholar
  107. Underwood MD, Khaibulina AA, Ellis SP, Moran A, Rice PM, Mann JJ, Arango V.: Morphometry of the dorsal raphe nucleus serotonergic neurons in suicide victims. Biol Psychiatry 1999; 46: 473–483.PubMedGoogle Scholar
  108. van Praag HM, Korf J.: Retarded depression and dopamine metabolism. Psychopharmacologia 1971; 19: 199–203.PubMedGoogle Scholar
  109. Willner P.: Dopaminergic mechanisms in depression and mania In: Bloom FE and Kupfer DJ (eds). Psychopharmacology: The Fourth Generation of Progress. Raven Press, Ltd., New York, NY, 1995; pp 921–931.Google Scholar
  110. Yates M, Leake A, Candy JM, Fairbairn AF, McKeith IG, Ferrier IN.: 5HT2 receptor changes in major depression. Biol Psychiatry 1990; 27: 489–496.PubMedGoogle Scholar
  111. Yatham LN, Liddle PF, Shiah IS, Scarrow G, Lam RW, Adam MJ, Zis AP, Ruth TJ.: Brain serotonin 2 receptors in major depression: a positron emission tomography study. Arch Gen Psychiatry 2000; 57: 850–858.PubMedGoogle Scholar
  112. Young LT, Li PP, Kish SJ, Warsh JJ.: Cerebral cortex beta-adrenoceptor binding in bipolar affective disorder. J Affect Disord 1994; 30: 89–92.PubMedGoogle Scholar
  113. Zhu MY, Klimek V, Dilley GE, Haycock JW, Stockmeier C, Overholser JC, Meltzer HY, Ordway GA.: Elevated levels of tyrosine hydroxylase in the locus coeruleus in major depression. Biol Psychiatry 1999; 46: 1275–1286.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2002

Authors and Affiliations

  • Craig A. Stockmeier
  • George Jurjus

There are no affiliations available

Personalised recommendations